The mesolimbic dopamine system and cAMP-dependent͞protein kinase A (PKA) pathways are strongly implicated in addictive behaviors. Here we determine the role of dopamine D2 receptors (D2) in PKA signaling responses to ␦-opioid (DOR) and cannabinoid (CB1) receptors. We find in NG108-15͞D2 cells and in cultured primary neurons that a brief exposure to saturating concentrations of DOR and CB1 agonists increases cAMP, promotes PKA C␣ translocation and increases cAMP-dependent gene expression. Activation of PKA signaling is mediated by Gi-␤␥ dimers. Importantly, subthreshold concentrations of DOR or CB1 agonists with D2 agonists, which are without effect when added separately, together activate cAMP͞PKA signaling synergistically. There is also synergy between DOR or CB1 with ethanol, another addicting agent. In all instances, synergy requires adenosine activation of adenosine A2 receptors and is mediated by ␤␥ dimers. Synergy by this molecular mechanism appears to confer hypersensitivity to opioids and cannabinoids while simultaneously increasing the sensitivity of D2 signaling when receptors are expressed on the same cells. This mechanism may account, in part, for drug-induced activation of medium spiny neurons in the nucleus accumbens.
A
lthough addicting drugs produce different clinical responses, they share the common characteristic of causing addiction. This suggests that a molecular mechanism shared by addicting drugs could contribute to the development of addiction. All addicting substances increase extracellular dopamine in the nucleus accumbens (NAc) (1, 2), a striatal component of reward and addiction (3) . cAMP͞protein kinase A (PKA) signaling is also involved in addiction (2) . Dopamine D2 (D2), ␦-opioid (DOR), and cannabinoid (CB1) receptors inhibit adenylyl cyclase (AC) activity (2) by activating inhibitory GTP-binding proteins, Gi͞o. Gi͞o consists of ␣i͞o and ␤␥ subunits; ␣i͞o inhibits AC. ␤␥ dimers have several effects (4) , including stimulation of AC isozymes II and IV (5-7). D2 activates AC II and IV, apparently via ␤␥ dimers (8) . ␤␥ dimers are required to maintain voluntary alcohol consumption in rats (9) .
NG108-15͞D2 (NG) cells express functional DOR (10) and CB1 (11) , as do rat primary hippocampal neurons (PHN). We report here that DOR and CB1 increase cAMP and stimulate PKA C␣ translocation in these cells at 10 min followed by increased cAMP-dependent gene transcription 5 h later. We also find synergy for PKA signaling and gene expression between subthreshold concentrations of DOR or CB1 agonists with ethanol or D2. In all instances, synergy requires adenosine and is mediated by ␤␥ dimers. Synergy appears to confer hypersensitivity simultaneously to DOR, CB1, and D2 when expressed on the same neurons with adenosine A2 (A2) receptors. ]enkephalin (DADLE), methanandamide (Met), UK 14304 (UK), carbachol (Carb), spiperone (Spip), naltrindole (Nal), AM 281 (AM), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), 3,7-dimethyl-1-(2-propynyl)xanthine (DMPX), and pertussis toxin (PTX) were from Sigma͞RBI (Natick, MA); Rp-cAMPS (Rp) was from BioLog (La Jolla, CA); pCRELuciferase (Luc) was from Stratagene; and pCMV ␤-galactosidase was from Qiagen (Hilden, Germany).
Cell Culture. NG and PHN were prepared and used exactly as described in ref. 9 . Drugs were added to NG cells on day 4 and to primary cultures on day 10. Viral Vectors. Construction and production of recombinant Ad5QEHA, Ad5SKEE, Ad5␤ARK1, and Ad5LacZ vectors were as described in ref. 9 . To make the HSVLacZ͞CRE-Luc construct, the LacZ gene was cloned into pHSVPrpUC under control of the HSV1 endogenous IE4͞5 promoter. A CRE-Luc expression cassette was then inserted downstream of the LacZ gene in reverse orientation. To produce the virus, 2-2 cells were transfected with the construct by using the Lipofectamine reagent as described by the manufacturer (GIBCO͞BRL) and superinfected with the helper virus 5dl1.2. After amplification three times on 2-2 cells, the virus was purified and titrated as described in ref. 12 .
CRE-Luciferase Reporter Assay. Luc was assayed in NG cells exactly as described (9) . Rat PHN were plated at 2.5 ϫ 10 4 cells per 24-well plate, grown for 10 days in Neurobasal A medium supplemented with B27 and glutamate, and then cultured in Neurobasal A medium only for 2 days. Cells were then infected overnight with HSVLacZ͞CRE-Luc at 1 multiplicity of infection. The cells were then treated with drugs for 10 min, washed, and cultured for 4 h before Luc assay. Luc in PHN was normalized for transfection efficiency as determined by ␤-galactosidase activity (Stratagene).
All procedures were performed in accordance with protocols approved by the Gallo Center Institutional Animal Care and Use Committee protocols and the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
Results
Activation of DOR or CB1 Induces PKA C␣ Translocation in NG Cells.
NG cells were incubated for 10 min with the DOR agonist, DADLE (1 M), or the CB1 agonist, Met (2 M), and trans-location of C␣ was measured with specific antibodies. DADLE and Met each causes translocation of C␣ away from the Golgi to the nucleus and cytoplasm, as does forskolin (Fig. 1A) . Nal (10 M), a DOR antagonist, or AM (10 M), a CB1 antagonist, blocks PKA C␣ translocation induced by DADLE or Met, respectively (Fig. 1 A) . By contrast, Gi͞o-coupled ␣2 adrenergic (␣2) (10 M UK) or M4-cholinergic (M4) (10 M Carb) agonists are without effect (Fig. 1 A) . Western blot analysis confirms these findings (Fig. 1B) .
DOR or CB1 Agonists Transiently Increase cAMP. Activation of PKA requires cAMP. DADLE increases cAMP levels at 10 min in NG cells, followed by decreases at 30 min (Fig. 1C) . Similar results were found with Met. ␣2 or M4 agonists, which do not cause C␣ translocation ( Fig. 1 A and B) , only reduce cAMP (Fig. 1C) . Minor increases in cAMP can activate PKA (13) . Rp (20 M), which prevents cAMP binding to the regulatory subunit of PKA, blocks DADLE-or Met-induced C␣ translocation (Fig. 1D) .
␤␥ Dimers Mediate DOR and CB1-Induced PKA C␣ Translocation. We next asked whether ␤␥ released from activated Gi͞o mediates DADLE-or Met-induced PKA translocation. PTX (50 ng͞ml), which prevents release of ␤␥ from Gi͞o, blocked DADLE-and Met-induced PKA C␣ translocation (Fig. 1D) . Adenoviral vectors expressing the ␤␥ inhibitor peptide ␤ARK1 (7) or QEHA (14) , also prevented DOR-and CB1-induced PKA C␣ translocation (Fig. 1E) . Overexpression of the inactive control peptide SKEE (15) was without effect. These data suggest that ␤␥ dimers mediate DADLE-and Met-induced PKA C␣ translocation, presumably by stimulating AC.
DADLE and Met Activate CRE-Mediated Gene Expression. We next asked whether DOR or CB1 induces cAMP-dependent gene expression. DADLE and Met each increases CRE-Luc 5 h after a 10-min exposure, as does 1 M forskolin (Fig. 1F) . ␣2 or ⌴4 agonists are without effect. DOR and CB1 antagonists block DADLE or Met stimulation of Luc, as does Rp (Fig. 1F) . Moreover, PTX (Fig. 1F ) or QEHA (data not shown) also prevents this response. These data suggest that DOR and CB1 activate CRE-Luc via PKA C␣ translocation to the nucleus.
Synergy Between DOR or CB1 Agonists with a D2 Agonist or Ethanol.
PKA C␣ translocation. Activation of PKA signaling by DOR and CB1 agonists suggested the possibility of synergy between ␤␥ dimers with ethanol͞A2 activation via G␣s (9) . Low concentrations of DADLE (0.01 nM), Met (0.02 nM), NPA (0.5 nM), or ethanol (25 mM) alone do not cause PKA C␣ translocation ( Fig.  2 B and C) . However, these subthreshold concentrations caused a synergistic induction of PKA C␣ translocation when DADLE or Met were coincubated with NPA or ethanol ( Fig. 2 A-C) . DADLE with Met did not produce synergy (not shown). CRE-mediated gene expression. Subthreshold concentrations of DADLE, Met, or NPA did not stimulate cAMP-dependent gene expression (Table 1) . However, coincubation of subthreshold concentrations of DADLE or Met for 10 min with NPA or ethanol increased CRE-Luc 5 h later by 54-67%; forskolin (8) induced an 87% increase (Table 1 ). Synergy involving DADLE or Met is blocked by Nal (10 M) and AM (10 M), respectively (not shown). There is no synergy between DADLE and Met (Table 1) .
Synergy for PKA C␣ Translocation and CRE-Mediated Gene Expression
Is Mediated by ␤␥-Dependent PKA Activation. Rp inhibits synergy for PKA C␣ translocation between DADLE or Met with NPA or ethanol (Fig. 2 A) . Synergy is also blocked by QEHA (Fig. 2 A) and by PTX (data not shown). Rp, PTX, or QEHA each inhibits synergistic activation of CRE-Luc (Table 1) .
A2 Receptors Are Required for Synergy. We have reported that ethanol increases PKA signaling via A2 receptors (16, 17) . A2 synergizes with D2 to increase cAMP (9, 18) . We asked whether adenosine also plays a role in synergy between DOR or CB1 with D2. The adenosine receptor antagonist BW A1434U (BW) (10 M), a gift from Glaxo͞Wellcome, does not affect PKA C␣ translocation (data not shown) or gene expression (Fig. 2E ) induced by saturating concentrations of DADLE (1 M) or Met (2 M). In contrast, BW blocks synergy for PKA translocation between subthreshold concentrations of DOR or CB1 agonists with NPA or ethanol (Fig. 2B ). Adenosine deaminase (1 unit͞ ml), which degrades adenosine, prevents synergy (Fig. 2C) . Adenosine receptor blockade also prevents synergistic increases in cAMP-dependent gene expression at the same low concentrations of agonists (Fig. 2D ). This appears to be caused by A2 because A1 receptors are not expressed in NG cells under these conditions of study (A.S.G. and I.D., unpublished data). Taken together, our data support the model presented in Fig. 4 that synergy for cAMP-dependent gene expression is caused by ␤␥ and A2͞G␣s activation and translocation of PKA C␣ to the nucleus.
PHN Exhibit DADLE-and Met-Induced Synergy with NPA or Ethanol.
PKA C␣ translocation. To validate findings in transformed NG cells, we also studied untransformed PHN. Immature rat PHN express D2 (19) , CB1 (20) , DOR (21), A2, and A1 (9) . Here, saturating levels of DADLE (1 M) or Met (2 M) induce PKA C␣ translocation to the cytoplasm, neurites, and nuclei in 10 min (Fig. 3 A and B) . DOR or CB1 antagonists block DADLE or Met-induced translocation, respectively (Fig. 3A) . As in NG cells, Rp, PTX, and QEHA each prevents DADLE-or Metinduced PKA C␣ translocation (Fig. 3B) . Synergy for translocation occurs at subthreshold concentrations of DADLE (0.01 nM) or Met (0.02 nM) with NPA (0.5 nM) or ethanol (25 mM) (Fig. 3C) . Rp, PTX, and QEHA also prevent synergy (not shown). CRE-mediated gene expression. Saturating concentrations of DADLE, Met, and NPA each increases Luc in PHN almost as effectively as forskolin (Table 2) . DOR-, CB1-, and D2-mediated increases are blocked by their respective antagonists as well as by Rp, PTX, and QEHA (Table 2 ). Adenosine receptor blockade 
Data are the mean Ϯ SEM of at least three experiments. *Previously reported in ref. 9 . **P Ͻ 0.01 compared with control (one-way analysis of variance and Dunnett's test). only prevented ethanol-induced increases in Luc without affecting DOR-, CB1-, or D2-mediated increases (Table 2 ). M4 and ␣2 agonists did not induce Luc (Table 2) . Subthreshold concentrations of DADLE or Met exhibited synergy with NPA or ethanol (Table 3) . Synergy was blocked by Rp, PTX, and QEHA ( Table  3 ), indicating that synergy in untransformed PHN occurs by the same mechanism as in transformed NG cells (Fig. 4) .
Adenosine Receptor Activation Is Required for Synergy. We asked whether adenosine receptors are required for synergy between DADLE or Met with NPA or ethanol in PHN. Three adenosine receptor antagonists were used: the general antagonist BW, the A1 antagonist DPCPX (100 nM), and the A2 antagonist DMPX (10 M). All three antagonists prevent synergy for PKA C␣ translocation ( Fig. 3C ) (data for BW not shown). These results suggest that both A1 and A2 receptors are required for synergy in immature PHN. In the CNS, A1 are usually presynaptic, whereas A2 are predominantly postsynaptic (38) . In our in vitro studies, Gi͞o-coupled A1 receptors are probably postsynaptic and may contribute to synergy via ␤␥ dimers. Preincubation with 1 M tetrodotoxin (TTX) for 2 h was without effect, indicating that presynaptic neurotransmitter release is not required. BW also blocks synergistic increases in CRE-Luc induced by subthreshold concentrations of DADLE or Met with NPA or ethanol (Table 3) . Taken together, our data suggest that PHN in culture exhibit DOR-, CB1-, and D2-induced ␤␥-dependent PKA C␣ translocation and increased cAMP-dependent gene expression. Synergy for PKA C␣ translocation and gene expression is also observed and appears to require adenosine and ␤␥ dimers.
Discussion
Our major findings are illustrated schematically in Fig. 4 . First, activation of Gi͞o-coupled DOR and CB1 by saturating concentrations of agonists increases PKA signaling and cAMPdependent gene transcription via ␤␥ dimers. Second, transient increases in cAMP and PKA C␣ translocation to the nucleus observed at 10 min were sufficient to increase cAMP-dependent CRE-mediated gene expression hours later. Third, and most important, there is a remarkable synergy for PKA signaling between DOR or CB1 with D2 agonists or ethanol. Subthreshold concentrations of DADLE or Met, which are without effect Table 2 . CRE-mediated luciferase activity in PHN Treatment % increase over control
78 Ϯ 7* *P Ͻ 0.01 compared with control as in Table 1 . 
*P Ͻ 0.01 compared with control as in Table 1 . Fig. 4 . Schematic representation of postsynaptic DOR, CB1, and D2 activation-induced PKA C␣ translocation and CRE-mediated gene expression via ␤␥ dimers. A central role for ␤␥ subunits released from Gi͞o is proposed for DOR, CB1, and D2. This diagram indicates synergy between subthreshold levels of DOR or CB1 (blue arrows) with D2 (red arrows). Synergy for PKA translocation and CRE-mediated gene expression is mediated by ␤␥ dimers from Gi͞o. Adenosine A2 activation via G␣s is required for synergy. We propose that colocalization of A2, D2, DOR, and CB1 on the same neurons, like in NAc, confers hypersensitivity to exogenous opioids, cannabinoids, and ethanol because of synergy. In addition, synergy promotes simultaneous hypersensitivity of postsynaptic D2 signaling that is characteristic of addicting drugs.
alone, when added together with subthreshold concentrations of NPA or ethanol induce a synergistic increase in PKA C␣ translocation and cAMP-dependent gene expression. In all instances, synergy appears to require adenosine and is mediated by ␤␥ dimers. Thus, adenosine and ␤␥ dimers appear to confer hypersensitivity simultaneously to DOR, CB1, and D2 agonists when expressed on the same cells. cAMP͞PKA signaling is involved in neural responses to opioids and cannabinoids in cellular (9) and animal (2, 21-23) models of addiction and withdrawal. We find that saturating concentrations of DOR and CB1 agonists increase cAMP levels at 10 min, whereas M4 and ␣2 agonists do not. Nevertheless, all of these receptors inhibit cAMP production when assayed at 30 min. These findings suggest that short-term activation of Gi͞o-coupled receptors involved in addiction appears to stimulate AC and PKA translocation. This leads to cAMP-dependent gene expression hours later. Overexpression of ␤␥ inhibitor peptides blocks DOR-or CB1-induced PKA translocation and gene expression, probably by preventing ␤␥ activation of AC (9, 22) . Adenosine is not required. This is in contrast to ethanol, which requires adenosine to activate cAMP production via A2͞G␣s (17) . Thus, our results suggest that saturating concentrations of DADLE or Met compared with ethanol appear to share a common characteristic; brief exposure to these agents increases PKA signaling by Gi͞o ␤␥ dimers or G␣s, respectively.
Our model cell systems allowed us to investigate the consequences of DOR and CB1 activation of AC. We find that cAMP-dependent gene transcription is demonstrable 5 h later, when cAMP levels are no longer increased. This finding is consistent with current concepts that cAMP-dependent gene expression persists long after cAMP produced by receptor activation has been degraded (23) . Indeed, prolonged responses involving PKA signaling may help to explain the observation that a single dose of ethanol (which increases cAMP͞PKA signaling) potentiates ␥-aminobutyric acidergic synaptic function for Ϸ7 days (24) . Potentiation is PKA-dependent and appears to contribute to increased ethanol consumption. Our findings that brief exposures to addicting substances produce significant increases in cAMP-dependent gene expression are consistent with the pathophysiologic importance of PKA in the development of addiction (2) .
We also find a striking synergy between subthreshold concentrations of DOR or CB1 agonists with ethanol to potentiate PKA signaling and cAMP-dependent gene expression. Ethanol increases cAMP by promoting A2 activation of G␣s (25) . Because G␣s is required for ␤␥ dimer stimulation of AC II and IV (5), we presume that synergy between DOR or CB1 with ethanol is mediated by Gi͞o ␤␥ potentiation of ethanol͞G␣s-mediated increases in AC activity (Fig. 4) .
Addicting drugs use dopaminergic signaling (1). Here we find that subthreshold concentrations of DOR or CB1 agonists hypersensitize D2 signaling by synergy with D2 agonists. Based on these data, we would predict that D2 contributes to opiateseeking behavior and physical dependence, and that D2 antagonists would have the opposite effect. This has been confirmed in animal studies (29) . Dopamine agonists mimic heroin priming (26, 27) , and D2 antagonists produce signs of withdrawal in morphine-dependent rodents (28) . Mice lacking D2 show reduced morphine self-administration (29) and a lack of opiate rewarding responses (29, 30) , but not everyone agrees (31) . In a different experimental setting, functional evidence consistent with synergy mediated by ␤␥ dimers has been reported in pain studies. After prior stimulation of Gs-coupled receptors by prostaglandin, opioid activation of a Gi͞o-coupled receptor produces a paradoxical cAMP-dependent hyperalgesia in rats that is blocked by a ␤␥ inhibitor (32) . There is also evidence that D2 activation increases release of cannabinoids (33) and that cannabinoids potently increase dopaminergic signaling (34) . Here our data documenting synergy between CB1 and D2 are supported indirectly by the observation that D2 agonists potentiate cannabinoid-induced sedation at doses that are ineffective alone (35) .
The striatum is enriched with postsynaptic A2 (36) . Also, A2 and D2 appear to be coexpressed very closely with each other on the same striatal neurons, in contrast to most other brain regions (37) (38) (39) (40) (41) (42) . Others have shown that synergy between A2 and D2 increases cAMP in PC12 cells (18) . Our model (Fig. 4) suggests that the presence of A2 and D2 with DOR and CB1 on the same neurons appears to confer hypersensitivity to exogenous DOR and CB1 agonists for activation of PKA signaling. Because synergy also confers hypersensitivity to D2 agonists, synergy would be expected to hypersensitize drug-induced activation of D2 signaling in the ventral tegmental area (VTA)-NAc pathway.
All instances of synergy appear to require adenosine and A2 receptors. Thus, degradation of adenosine by adenosine deaminase or adenosine receptor blockade prevents synergy. However, it is not clear how synergy develops between DOR or CB1 with D2. The simplest explanation for our data is that synergy of DOR or CB1 with D2 increases extracellular adenosine. However, unlike ethanol (25), NPA does not significantly inhibit adenosine uptake (unpublished observation), and it remains to be determined how synergy promotes A2 activation. Nevertheless, we would predict that A2 agonists potentiate drug-seeking behavior, whereas A2 antagonists would do the opposite. This hypothesis is supported by a recent report in which A2 agonists potentiate morphine selfadministration in rats, whereas A2 antagonists block this addictive behavior (43) . In addition, opioid agonists appear to decrease adenosine uptake in striatal cells (44) , and chronic morphine increases the sensitivity of excitatory postsynaptic currents to adenosine inhibition in the NAc, apparently by decreasing adenosine uptake (45) .
Adenosine receptor agonists and morphine produce similar physical dependence and bidirectional cross-withdrawal syndromes in response to receptor antagonists (46) . Thus, naloxone, an opioid antagonist, precipitates adenosine withdrawal and an A1͞A2 antagonist provokes morphine withdrawal. Also, adenosine receptor antagonists attenuate the development of morphine sensitization in mice (47) . In humans, adenosine infusions strikingly reduce the requirement for opiates for postoperative pain (48) . These behavioral and clinical observations support our hypothesis that ␤␥-mediated synergy produced by low concentrations of exogenous opioid agonists in the presence of endogenous adenosine regulates responses to opiates. We propose that adenosine and ␤␥ dimers are components of a postsynaptic molecular mechanism that hypersensitizes dopaminergic signaling in the presence of opioids, cannabinoids, and ethanol and may contribute to their self-administration. This suggests that adenosine receptor antagonists might attenuate the development of addiction.
